Free Trial

Johnson & Johnson (JNJ) Competitors

$156.58
+5.57 (+3.69%)
(As of 07/17/2024 ET)

JNJ vs. LLY, MRK, ABBV, PFE, ZTS, BMY, RPRX, JAZZ, PRGO, and CORT

Should you be buying Johnson & Johnson stock or one of its competitors? The main competitors of Johnson & Johnson include Eli Lilly and Company (LLY), Merck & Co., Inc. (MRK), AbbVie (ABBV), Pfizer (PFE), Zoetis (ZTS), Bristol-Myers Squibb (BMY), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), and Corcept Therapeutics (CORT). These companies are all part of the "pharmaceuticals" industry.

Johnson & Johnson vs.

Eli Lilly and Company (NYSE:LLY) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, community ranking, dividends, risk and profitability.

Johnson & Johnson has a net margin of 45.26% compared to Johnson & Johnson's net margin of 17.08%. Johnson & Johnson's return on equity of 56.98% beat Eli Lilly and Company's return on equity.

Company Net Margins Return on Equity Return on Assets
Eli Lilly and Company17.08% 56.98% 10.94%
Johnson & Johnson 45.26%36.70%15.07%

Eli Lilly and Company pays an annual dividend of $5.20 per share and has a dividend yield of 0.6%. Johnson & Johnson pays an annual dividend of $4.96 per share and has a dividend yield of 3.2%. Eli Lilly and Company pays out 76.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Johnson & Johnson pays out 30.9% of its earnings in the form of a dividend. Johnson & Johnson has increased its dividend for 63 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Johnson & Johnson has higher revenue and earnings than Eli Lilly and Company. Johnson & Johnson is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eli Lilly and Company$35.93B23.95$5.24B$6.79133.34
Johnson & Johnson$85.65B4.40$35.15B$16.049.76

82.5% of Eli Lilly and Company shares are held by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are held by institutional investors. 0.1% of Eli Lilly and Company shares are held by insiders. Comparatively, 0.2% of Johnson & Johnson shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Johnson & Johnson had 7 more articles in the media than Eli Lilly and Company. MarketBeat recorded 62 mentions for Johnson & Johnson and 55 mentions for Eli Lilly and Company. Eli Lilly and Company's average media sentiment score of 0.65 beat Johnson & Johnson's score of 0.61 indicating that Johnson & Johnson is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Eli Lilly and Company
25 Very Positive mention(s)
6 Positive mention(s)
13 Neutral mention(s)
5 Negative mention(s)
0 Very Negative mention(s)
Positive
Johnson & Johnson
32 Very Positive mention(s)
8 Positive mention(s)
11 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Eli Lilly and Company received 95 more outperform votes than Johnson & Johnson when rated by MarketBeat users. Likewise, 70.32% of users gave Eli Lilly and Company an outperform vote while only 65.08% of users gave Johnson & Johnson an outperform vote.

CompanyUnderperformOutperform
Eli Lilly and CompanyOutperform Votes
1187
70.32%
Underperform Votes
501
29.68%
Johnson & JohnsonOutperform Votes
1092
65.08%
Underperform Votes
586
34.92%

Eli Lilly and Company presently has a consensus target price of $858.72, indicating a potential downside of 5.16%. Johnson & Johnson has a consensus target price of $174.07, indicating a potential upside of 11.17%. Given Eli Lilly and Company's higher probable upside, analysts plainly believe Johnson & Johnson is more favorable than Eli Lilly and Company.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eli Lilly and Company
0 Sell rating(s)
3 Hold rating(s)
16 Buy rating(s)
0 Strong Buy rating(s)
2.84
Johnson & Johnson
0 Sell rating(s)
8 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.38

Eli Lilly and Company has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500.

Summary

Johnson & Johnson beats Eli Lilly and Company on 13 of the 21 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JNJ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

JNJ vs. The Competition

MetricJohnson & JohnsonPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$363.43B$7.21B$5.30B$18.56B
Dividend Yield3.31%2.75%2.76%3.49%
P/E Ratio9.7619.70134.4225.45
Price / Sales4.40483.052,253.0716.55
Price / Cash10.9233.3235.3820.26
Price / Book5.485.934.985.14
Net Income$35.15B$147.02M$110.54M$974.76M
7 Day Performance4.80%6.28%5.38%5.37%
1 Month Performance7.27%8.23%8.10%6.48%
1 Year Performance-1.56%-1.57%6.29%10.05%

Johnson & Johnson Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LLY
Eli Lilly and Company
4.8741 of 5 stars
4.87 / 5 stars
$941.60
-0.9%
$858.72
-8.8%
+102.5%$894.91B$34.12B138.6743,000Analyst Forecast
Analyst Revision
Gap Down
MRK
Merck & Co., Inc.
4.5683 of 5 stars
4.57 / 5 stars
$125.44
-2.1%
$135.36
+7.9%
+19.2%$317.72B$60.12B139.3872,000Positive News
ABBV
AbbVie
4.5868 of 5 stars
4.59 / 5 stars
$169.20
+0.7%
$182.69
+8.0%
+30.0%$298.79B$54.32B50.2150,000Upcoming Earnings
Ex-Dividend
Short Interest ↑
PFE
Pfizer
4.749 of 5 stars
4.75 / 5 stars
$29.49
+1.3%
$34.50
+17.0%
-16.3%$167.11B$58.50B-491.4288,000
ZTS
Zoetis
4.5718 of 5 stars
4.57 / 5 stars
$183.08
+2.9%
$211.75
+15.7%
+6.6%$83.54B$8.54B35.2814,100
BMY
Bristol-Myers Squibb
4.7855 of 5 stars
4.79 / 5 stars
$41.20
+2.6%
$59.07
+43.4%
-30.2%$83.52B$45.01B-13.2934,100Options Volume
Analyst Revision
RPRX
Royalty Pharma
4.8019 of 5 stars
4.80 / 5 stars
$27.69
+3.9%
$41.80
+51.0%
-8.3%$16.54B$2.36B20.6651Positive News
JAZZ
Jazz Pharmaceuticals
4.958 of 5 stars
4.96 / 5 stars
$106.09
+2.7%
$185.86
+75.2%
-14.4%$6.69B$3.83B21.872,800
PRGO
Perrigo
4.9337 of 5 stars
4.93 / 5 stars
$27.09
+0.7%
$39.33
+45.2%
-16.5%$3.69B$4.66B-387.009,140
CORT
Corcept Therapeutics
4.8052 of 5 stars
4.81 / 5 stars
$33.34
+3.1%
$45.10
+35.3%
+44.9%$3.47B$482.38M31.45352Positive News

Related Companies and Tools

This page (NYSE:JNJ) was last updated on 7/18/2024 by MarketBeat.com Staff

From Our Partners